Dr. Reddy's Laboratories launches Colesevelam Hydrochloride Tablets in the U.S. Market
Deepthi | Myequity news | Date : 09-10-2018 18:55:00 IST
Dr. Reddy's Laboratories Ltd. has launched Colesevelam HCI Tablets, USP, a therapeutic equivalent generic version of WELCHOL (colesevelam HCI) Tablets in the United States market approved by the U.S. Food and Drug Administration (USFDA).
The WELCHOL brand and generic had U.S. sales of approximately $471 million MAT for the most recent twelve months ending in August 2018 according to IMS Health*.
Dr. Reddy's Colesevelam Hydrochloride Tablets is available in 625 mg with 180 count bottle size. WELCHOL is a registered trademark of Daiichi Sankyo, Inc.
About Dr. Reddy's:
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe.